Zacks Research Brokers Raise Earnings Estimates for Novartis

Novartis AG (NYSE:NVS) – Equities research analysts at Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for shares of Novartis in a note issued to investors on Tuesday, June 24th. Zacks Research analyst E. Bagri now expects that the company will earn $2.28 per share for the quarter, up from their previous forecast of $2.24. The consensus estimate for Novartis’ current full-year earnings is $8.45 per share. Zacks Research also issued estimates for Novartis’ Q2 2026 earnings at $2.38 EPS, Q4 2026 earnings at $2.20 EPS, FY2026 earnings at $9.10 EPS, Q1 2027 earnings at $2.38 EPS and FY2027 earnings at $9.63 EPS.

Separately, BNP Paribas raised Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Trading Up 2.0%

Novartis stock opened at $120.36 on Thursday. The business has a 50 day moving average price of $113.76 and a two-hundred day moving average price of $107.94. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.56. The stock has a market cap of $254.24 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 1.70 and a beta of 0.59. Novartis has a 12 month low of $96.06 and a 12 month high of $120.92.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.12 by $0.16. The firm had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $12.92 billion. Novartis had a return on equity of 39.44% and a net margin of 24.70%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.80 EPS.

Hedge Funds Weigh In On Novartis

A number of hedge funds have recently modified their holdings of NVS. Raiffeisen Bank International AG acquired a new position in shares of Novartis in the 4th quarter worth approximately $25,000. Nexus Investment Management ULC acquired a new position in shares of Novartis in the 1st quarter worth approximately $25,000. WPG Advisers LLC acquired a new position in shares of Novartis in the 1st quarter worth approximately $25,000. Tsfg LLC raised its holdings in shares of Novartis by 366.0% in the 1st quarter. Tsfg LLC now owns 233 shares of the company’s stock worth $26,000 after buying an additional 183 shares in the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the 4th quarter worth approximately $27,000. 13.12% of the stock is owned by institutional investors and hedge funds.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.